Literature DB >> 2459193

Acid-induced conformational modification of the hemagglutinin molecule alters interaction of influenza virus with antigen-presenting cells.

L C Eisenlohr1, W Gerhard, C J Hackett.   

Abstract

Brief exposure of influenza virus to pH 5 was found to have extensive effects upon presentation of viral Th cell antigenic determinants. This acidity, comparable to that encountered in host cell endosomes, was known to effect conformational changes in the viral hemagglutinin (HA) which alter the molecule's fusion activity, antigenicity, and susceptibility to enzymes. Three major effects of low pH upon presentation of viral T cell determinants were observed: first, acid pretreatment permitted presentation by pre-fixed APC of two of three linear T cell sites of the HA molecule, bypassing the APC activity required to present untreated virus; second, the two determinants presented in this manner disappeared rapidly from APC surfaces; third, acid-pretreated virus was not efficiently utilized by active APC in the normal pathway of viral antigen presentation. These observations suggest that the pH-induced conformational transition of HA may constitute sufficient processing for certain linear determinants of the molecule and additionally influences the processes involved in the general formation and presentation of viral T cell sites.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459193

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Constitutive endocytosis and recycling of major histocompatibility complex class II glycoproteins in human B-lymphoblastoid cells.

Authors:  P A Reid; C Watts
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

2.  Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice.

Authors:  W Gerhard; A M Haberman; P A Scherle; A H Taylor; G Palladino; A J Caton
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis?

Authors:  Brian P Dolan; Jonathan J Knowlton; Alexandre David; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

Review 4.  Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus.

Authors:  C J Hackett; L C Eisenlohr
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

5.  Intracellular hemolysin-producing Listeria monocytogenes strains inhibit macrophage-mediated antigen processing.

Authors:  C W Cluff; M Garcia; H K Ziegler
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

6.  Mutation in Hemagglutinin Antigenic Sites in Influenza A pH1N1 Viruses from 2015-2019 in the United States Mountain West, Europe, and the Northern Hemisphere.

Authors:  Craig H Decker; Naomi Rapier-Sharman; Brett E Pickett
Journal:  Genes (Basel)       Date:  2022-05-19       Impact factor: 4.141

7.  Immunogenicity of free synthetic peptides corresponding to T helper epitopes of the influenza HA 1 subunit. Induction of virus cross reacting CD4+ T lymphocytes in mice.

Authors:  C Schneider; M H Van Regenmortel
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin.

Authors:  Jonathan W Yewdell
Journal:  Mol Immunol       Date:  2010-01-04       Impact factor: 4.407

9.  Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis.

Authors:  L C Eisenlohr; C J Hackett
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.